# A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)

> **NCT00473889** · PHASE2,PHASE3 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 253 (actual)

## Conditions studied

- Stage IIIB or IV Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** vorinostat
- **DRUG:** Comparator: paclitaxel
- **DRUG:** Comparator: carboplatin
- **DRUG:** Comparator: placebo

## Key facts

- **NCT ID:** NCT00473889
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-05
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 253 (ACTUAL)
- **Why stopped:** The study was terminated based on the recommendation by the DSMB following a pre-planned protocol interim analysis because the endpoint was not achieved.
- **Last updated:** 2015-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00473889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00473889, "A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00473889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*